1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 分子タイプ別スニペット
3.2. 薬剤クラス別スニペット
3.3. 用途別スニペット
3.4. 投与経路別スニペット
3.5. 販売チャネル別スニペット
3.6. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性疾患の増加と技術の進歩
4.1.1.2. XX
4.1.2. 阻害要因
4.1.2.1. 高い開発コスト
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 分子タイプ別
6.1. はじめに
6.1.1. 分子タイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（分子タイプ別
6.2. 低分子*市場
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 大型分子
7. 薬剤クラス別
7.1. 序論
7.1.1. 薬効分類別市場規模分析および前年比成長率分析（%） 7.1.2.
7.1.2. 市場魅力度指数（薬効分類別
7.2. モノクローナル抗体（mAbs）*市場
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. サイトカイン
7.4. インスリン
7.5. ペプチドホルモン
7.6. ワクチン
7.7. 免疫グロブリン
7.8. 血液因子
7.9. ペプチド抗生物質
7.10. その他
8. 用途別
8.1. 導入
8.1.1. 用途別市場規模分析および前年比成長率分析(%)
8.1.2. 市場魅力度指数（流通チャネル別
8.2. オンコロジー*市場
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 心血管疾患
8.4. 神経
8.5. 自己免疫疾患
8.6. 感染症
8.7. 糖尿病
8.8. その他
9. 投与経路別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（%）、流通チャネル別
9.1.2. 市場魅力度指数（流通チャネル別
9.2. 皮下（SC）*市場
9.2.1. 序論
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 静脈内注射
9.4. 筋肉内注射（IM）
9.5. その他
10. 流通チャネル別
10.1. はじめに
10.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.1.2. 市場魅力度指数（流通チャネル別
10.2. 病院薬局
10.2.1. 序論
10.2.2. 市場規模分析と前年比成長率分析(%)
10.3. 小売薬局
10.4. オンライン薬局 *.
11. 地域別
11.1. はじめに
11.1.1. 地域別市場規模分析および前年比成長率分析(%)
11.1.2. 市場魅力度指数、地域別
11.2. 北米
11.2.1. 序論
11.2.2. 主な地域別ダイナミクス
11.2.3. 市場規模分析および前年比成長率分析（%）、分子タイプ別
11.2.4. 市場規模分析および前年比成長率分析（%）、薬物クラス別
11.2.5. 市場規模分析および前年比成長率分析（%）, 用途別
11.2.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.2.7. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.2.8. 市場規模分析および前年比成長率分析（%）, 国別
11.2.8.1. 米国
11.2.8.2. カナダ
11.2.8.3. メキシコ
11.3. ヨーロッパ
11.3.1. はじめに
11.3.2. 主な地域別動向
11.3.3. 分子タイプ別市場規模分析および前年比成長率分析（%） 11.3.4.
11.3.4. 市場規模分析およびYoY成長率分析（%）、薬物クラス別
11.3.5. 市場規模分析および前年比成長率分析（%）, 用途別
11.3.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.3.7. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.3.8. 市場規模分析および前年比成長率分析（%）, 国別
11.3.8.1. ドイツ
11.3.8.2. イギリス
11.3.8.3. フランス
11.3.8.4. スペイン
11.3.8.5. イタリア
11.3.8.6. その他のヨーロッパ
11.4. 南米
11.4.1. はじめに
11.4.2. 地域別主要市場
11.4.3. 分子タイプ別市場規模分析および前年比成長率分析（%） 11.4.4.
11.4.4. 市場規模分析およびYoY成長率分析（%）、薬物クラス別
11.4.5. 市場規模分析および前年比成長率分析（%）, 用途別
11.4.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.4.7. 市場規模分析および前年比成長率分析 (%)、流通チャネル別
11.4.8. 市場規模分析および前年比成長率分析（%）, 国別
11.4.8.1. ブラジル
11.4.8.2. アルゼンチン
11.4.8.3. その他の南米諸国
11.5. アジア太平洋
11.5.1. はじめに
11.5.2. 主な地域別ダイナミクス
11.5.3. 分子タイプ別市場規模分析および前年比成長率分析（%） 11.5.4.
11.5.4. 市場規模分析およびYoY成長率分析（%）、薬物クラス別
11.5.5. 市場規模分析および前年比成長率分析（%）, 用途別
11.5.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.5.7. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.5.8. 市場規模分析および前年比成長率分析（%）, 国別
11.5.8.1. 中国
11.5.8.2. インド
11.5.8.3. 日本
11.5.8.4. 韓国
11.5.8.5. その他のアジア太平洋地域
11.6. 中東・アフリカ
11.6.1. 序論
11.6.2. 主な地域別ダイナミクス
11.6.3. 分子タイプ別市場規模分析および前年比成長率分析（%） 11.6.4.
11.6.4. 市場規模分析および前年比成長率分析（%）、薬物クラス別
11.6.5. 市場規模分析および前年比成長率分析（%）, 用途別
11.6.6. 市場規模分析および前年比成長率分析（%）, 投与経路別
11.6.7. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
12. 競合情勢
12.1. 競争シナリオ
12.2. 市場ポジショニング／シェア分析
12.3. M&A分析
13. 企業プロフィール
13.1. Pfizer Inc.*
13.1.1. 会社概要
13.1.2. 製品ポートフォリオと内容
13.1.3. 財務概要
13.1.4. 主な展開
13.2. Merck & Co., Inc.
13.3. Novartis AG
13.4. Sanofi
13.5. GSK plc
13.6. AbbVie Inc
13.7. F. Hoffmann-La Roche Ltd
13.8. Gilead Sciences, Inc.
13.9. Amgen Inc.
13.10. Teva Pharmaceuticals USA, Inc.(*リストは完全ではありません）
14. 付録
14.1. 会社概要とサービス
14.2. お問い合わせ
The Global Sterile Injectable Market reached US$ 577.32 billion in 2023 and is expected to reach US$ 1008.11 billion by 2031 growing with a CAGR of 7.8% during the forecast period 2024-2031.
The global sterile injectable market refers to the sector involving injectable pharmaceutical formulations administered directly into the bloodstream or human tissues. These formulations are critical for treating various medical conditions, especially chronic diseases, due to their rapid absorption and effectiveness compared to other forms of medication, such as oral tablets or sprays.
Sterile injectable medications are formulations that must be completely devoid of living microorganisms and are commonly administered through injections. This category encompasses various products, including vaccines, monoclonal antibodies, and other biological drugs.
These medications can be delivered via various routes, such as intravenous (IV) infusions, intramuscular (IM) shots, or subcutaneous (SC) injections. These administration methods enable rapid therapeutic action and targeted delivery of the active pharmaceutical ingredients directly into the bloodstream or specific tissues, bypassing potential barriers or degradation that may occur with other routes of administration.
Market Dynamics: Drivers
Rising prevalence of chronic diseases and technological advancements
The demand for the global sterile injectable market is driven by multiple factors. One of the primary factors is the rising prevalence of chronic diseases and technological advancements. The growing incidence of chronic illnesses worldwide, such as cancer, diabetes, and heart disease, is a significant driver propelling the sterile injectables market growth. Several injectable medications are utilized in the treatment of these chronic conditions, thereby stimulating the demand for sterile injectable formulations.
According to the World Health Organization (WHO) data in September 2023, indicating that chronic diseases are responsible for approximately 71% of global deaths highlights a significant public health challenge. Sterile injectable drugs have emerged as a crucial treatment modality for managing various chronic diseases. Moreover, ongoing advancements in prefilled syringes and autoinjectors are making injectable drug therapies increasingly convenient and user-friendly. These innovations are fueling greater adoption of injectable treatments by patients and healthcare providers.
In addition, major players in the industry investments such as the expansion of the market, and key development strategies are driving the market growth. For instance, in April 2023, Bridgewest Group launched a new Contract Development and Manufacturing Organization (CDMO) focused on sterile injectable drug products. This follows Bridgewest's recent acquisition of Pfizer's sterile injectable manufacturing plant in Perth, Australia.
Similarly, in July 2023, WuXi STA launched a state-of-the-art sterile injectable manufacturing line at its drug product facility in Wuxi City, China. The line has an annual capacity of 12 million units, allowing WuXi STA to meet the growing demand for sterile injectable drugs. The manufacturing process utilizes fully enclosed isolation systems and automated filling machines. This minimizes human intervention and exposure, enhancing product quality and worker safety.
Also, in August 2023, Pfizer implemented an emergency ordering process for certain sterile injectable products due to a significant increase in demand following a tornado that impacted its manufacturing plant in North Carolina. This emergency measure allows Pfizer to ship specific sterile injectables directly to customers, ensuring continued access to these critical medications during the disruption.
Restraints
Factors such as high development costs, stringent regulatory requirements, complex manufacturing processes, patent expiration & reimbursement challenges, are expected to hamper the market.
Market Segment Analysis
The global sterile injectable market is segmented based on molecule type, drug class, application, route of administration, distribution channels, and region.
The monoclonal antibodies (mAbs) segment accounted for approximately 40.6% of the global sterile injectable market share
The monoclonal antibodies (mAbs) segment is expected to hold the largest market share over the forecast period. The increasing use of monoclonal antibody (mAb) therapies to treat chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases is a significant factor driving demand for mAb injectables in the global sterile injectables market.
Moreover, key players in the industry's innovative product launches and approvals are helping to drive this segment growth in the market. For instance, in May 2024, Roche Pharma India officially entered the ophthalmology market with the launch of Vabysmo (faricimab), a groundbreaking treatment for neovascular or "wet" age-related macular degeneration (nAMD) and diabetic macular edema (DME). Both nAMD and DME are significant contributors to vision loss globally, affecting millions of individuals.
Similarly, in December 2023, KBI Biopharma, Inc., a subsidiary of JSR Life Sciences, launched SUREmAb, a new offering built on its SUREtechnology Platform. This innovative platform is designed to optimize the development and manufacturing processes of monoclonal antibodies (mAbs), making them more efficient, safe, and cost-effective.
Also, in June 2023, UCB announced that the U.S. Food and Drug Administration (FDA) has approved RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This approval marks a significant advancement in the treatment options available for gMG, a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles.
Market Geographical Analysis
North America accounted for approximately 43.6% of the global sterile injectable market share
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases, aging population, and well-advanced healthcare infrastructure, which are driving this market growth in this region.
Moreover, in this region, a major number of key players' presence, financial investments, government initiatives & support, and product launches are helping to propel this market growth. For instance, in July 2024, in New Jersey, Amneal Pharmaceuticals launched FOCINVEZ (fosaprepitant), a novel ready-to-use sterile injectable that offers several advantages over existing fosaprepitant products. FOCINVEZ was developed by SPES Pharmaceuticals, a specialized R&D firm focused on innovative formulations, and is manufactured by Steriscience, a global sterile injectables CDMO. The launch of this innovative fosaprepitant product represents an important new treatment option for patients undergoing chemotherapy, with its unique formulation and ease-of-use features designed to improve efficiency and safety in administration.
Similarly, in April 2024, Baxter International Inc., a global leader in injectables, anesthesia, and drug compounding, announced the launch of five new injectable products in the U.S., expanding its Pharmaceuticals portfolio. These launches demonstrate Baxter's focus on developing differentiated products that address unmet patient needs in critical therapeutic areas, including anti-infective and anti-hypotensive medications.
Also, in February 2024, Pharmascience, the largest Canadian-owned pharmaceutical company, announced a significant expansion of its sterile injectable manufacturing facility located in Candiac, Quebec, with a substantial investment of $120 million. This expansion is a pivotal milestone for the company as it aims to enhance its capabilities in producing sterile injectables and strengthen its position in the pharmaceutical market.
Market Segmentation
By Molecule Type
Small Molecule
Large Molecule
By Drug Class
Monoclonal Antibodies (mAbs)
Cytokines
Insulin
Peptide Hormones
Vaccines
Immunoglobulins
Blood Factors
Peptide Antibiotics
Others
By Application
Oncology
Cardiovascular Diseases
Neurology
Autoimmune Diseases
Infectious Diseases
Diabetes
Others
By Route of Administration
Subcutaneous (SC)
Intravenous (IV)
Intramuscular (IM)
Others
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the sterile injectable market include Pfizer Inc., Merck & Co., Inc., Novartis AG, Sanofi, GSK plc, AbbVie Inc., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Amgen Inc., and Teva Pharmaceuticals USA, Inc. among others.
Key Developments
In June 2024, Sharp Services announced a significant expansion of its facility in Macungie, Pennsylvania, aimed at enhancing its production capacity for sterile injectable secondary packaging. This strategic move is designed to meet the increasing demand for sterile injectables in the pharmaceutical and biotech sectors.
In June 2024, Bora Pharmaceuticals Co., Ltd. announced a significant step in its commercial expansion strategy by agreeing to acquire Emergent BioSolutions' sterile manufacturing facility located in Baltimore-Camden, Maryland. This acquisition marks Bora's first sterile manufacturing facility and is a strategic move to enhance its capabilities in sterile injectable drug product manufacturing.
In March 2023, Hikma Pharmaceuticals PLC announced the launch of four new sterile injectable medicines in Canada, marking a significant expansion of its product offerings in the region. This development is crucial for both patients and healthcare providers, as it introduces important new treatment options and reinforces Hikma's growing presence in the Canadian market.
Why Purchase the Report?
To visualize the global sterile injectable
Market Segmentation based on molecule type, drug class, application, route of administration, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the sterile injectable market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in excel consisting of key products of all the major players.
The global sterile injectable market report would provide approximately 78 tables, 82 figures, and 184 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Molecule Type
3.2. Snippet by Drug Class
3.3. Snippet by Application
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channels
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Chronic Diseases and Technological Advancements
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High Development Costs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Molecule Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
6.1.2. Market Attractiveness Index, By Molecule Type
6.2. Small Molecule*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Large Molecule
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Monoclonal Antibodies (mAbs) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cytokines
7.4. Insulin
7.5. Peptide Hormones
7.6. Vaccines
7.7. Immunoglobulins
7.8. Blood Factors
7.9. Peptide Antibiotics
7.10. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Oncology*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Diseases
8.4. Neurology
8.5. Autoimmune Diseases
8.6. Infectious Diseases
8.7. Diabetes
8.8. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Subcutaneous (SC) *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous (IV)
9.4. Intramuscular (IM)
9.5. Others
10. By Distribution Channels
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.1.2. Market Attractiveness Index, By Distribution Channels
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies *
10.4. Online Pharmacies *
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. U.K.
11.3.8.3. France
11.3.8.4. Spain
11.3.8.5. Italy
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Merck & Co., Inc.
13.3. Novartis AG
13.4. Sanofi
13.5. GSK plc
13.6. AbbVie Inc
13.7. F. Hoffmann-La Roche Ltd
13.8. Gilead Sciences, Inc.
13.9. Amgen Inc.
13.10. Teva Pharmaceuticals USA, Inc. (*LIST NOT EXHAUSTIVE)
14. Appendix
14.1. About Us and Services
14.2. Contact Us
❖ 世界の無菌注射剤市場に関するよくある質問(FAQ) ❖
・無菌注射剤の世界市場規模は？
→DataM Intelligence社は2023年の無菌注射剤の世界市場規模を5773.2億米ドルと推定しています。
・無菌注射剤の世界市場予測は？
→DataM Intelligence社は2031年の無菌注射剤の世界市場規模を1兆811億米ドルと予測しています。
・無菌注射剤市場の成長率は？
→DataM Intelligence社は無菌注射剤の世界市場が2024年～2031年に年平均7.8%成長すると予測しています。
・世界の無菌注射剤市場における主要企業は？
→DataM Intelligence社は「Pfizer Inc.、Merck & Co., Inc.、Novartis AG、Sanofi、GSK plc、AbbVie Inc.、F. Hoffmann-La Roche Ltd.、Gilead Sciences, Inc.、Amgen Inc.、Teva Pharmaceuticals USA, Inc.など ...」をグローバル無菌注射剤市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
